Purdue Pharma appoints Danerius’ Dunton SVP of R&D

STAMFORD, Conn. — Purdue Pharma on Thursday announced that it had appointed Dr. Alan Dunton to be its SVP of research and development, a role that will see him serve as the company’s lead scientist overseeing teams focused on research, clinical pharmacology, virtual discovery, project management, drug safety, pharmaceutics and analytics. He will also lead the company’s scientific development strategy, including its pipeline and clinical development.

“At a time of transformation for Purdue, Alan brings the right skills and experience to diversify and grow our portfolio,” Purdue Pharma CEO Mark Timney said. "We look forward to his contributions in optimizing our existing pipeline, while strengthening our presence in other therapeutic areas."

Dunton’s 33 years in the industry has seen him working on discovering and developing prescription and OTC products, leading the biotechnology company Danerius since 2006 when he founded it. Before that, he was president of CEO of Panacos Pharmaceuticals and Metaphore Pharmaceuticals. He also spent time at Janssen Research Foundation.

“Purdue Pharma has a well-established record of innovation in pain medicine that makes a positive impact on patient lives. I look forward to helping the Company continue its pioneering research in pain medicine, as well as innovative research in other areas of unmet need,” Dunton said.